Legal & General Group PLC Rotates AI Gains Into Big Pharma in 2026-Q1

The standout move is the new AstraZeneca position at 1.16% of the book, a ~$5.01B swing overnight into a diversified pharma platform. Paired with an add to Eli Lilly, this is a declaration that the fund wants structural exposure to obesity and oncology cash flows, not just AI-driven earnings revisions.

Within health care, they also boosted Johnson & Johnson and UnitedHealth, rounding out a defensive complex that can grind higher even if tech leadership pauses. These are not trading positions; they fit a multi-year view that innovation plus pricing power will compound through cycles.

Beyond drugs, the fund leaned into payments, increasing Visa and Mastercard, both long-duration cash machines that monetize global consumption and digital commerce without betting on any single retailer. Micron and Lam Research adds show they are still pressing the AI supply chain, but doing it via memory and equipment where upside is more tied to capacity and capex cycles than to already-priced perfection in the headline GPU names.

Other incremental adds — Goldman Sachs, Netflix, Caterpillar, Costco, McDonald’s, Procter & Gamble — sketch a preference for dominant franchises with proven pricing power and strong capital return, even in a choppier macro tape. The common thread is scale, cash generation and durable demand, with AI now one of several growth engines rather than the only story.

On the sell side, the message is controlled profit-taking, not a wholesale factor reversal. NVIDIA, Apple, Broadcom and Microsoft all saw modest share reductions (low single-digit percentages), yet remain among the largest holdings; this is a classic skim after huge gains rather than a vote of no confidence in AI or cloud.

Oracle stands out as a more decisive trim, with shares cut -8.8% and roughly $146.6M in exposure freed up. That suggests less enthusiasm for second-tier software names trying to retrofit AI into legacy stacks compared with infrastructure winners and pure-play data-center beneficiaries.

Amazon, Alphabet (both share classes), Meta and Cisco were all nicked rather than chopped, again pointing to position sizing discipline after a strong multi-quarter run. In energy, Exxon and Chevron, and in banks, JPMorgan, Bank of America, Wells Fargo and Citigroup, continue to be tapped as funding sources rather than destinations for new capital.

Even Berkshire Hathaway was reduced slightly, reinforcing the idea that generalized value exposure is less compelling than specific, high-conviction theses. Where they do still want cyclicality — Caterpillar, GE Vernova, Goldman — they are adding, not trimming, which sharpens the contrast with the names being used as liquidity.

Despite the trims, technology is still over half the book at 58.23%, down only modestly from 59.88%. The nuance is inside that bucket: they are shaving megacap platform leaders while increasing more cyclical AI enablers like Micron, Lam Research and Applied Materials, and keeping Intel exposure on a shorter leash.

Health care is where the real rotation is happening, jumping to 9.88% from 7.71% in a single quarter. The combination of a new AstraZeneca stake plus adds to Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth and Gilead re-weights the portfolio toward pipelines, specialty care, and managed-care scale.

Consumer exposure, at 11.21%, is being reshaped around resilient spend: tiny cuts to Walmart offset by adds to Netflix, Costco, Home Depot, McDonald’s and Procter & Gamble. Financials are stable in aggregate at 5.5%, but the mix is tilting from money-center banks toward capital-markets exposure via Goldman, which they increased.

Real estate, as labeled in the data, mostly captures payment networks and REITs; there the story is more Visa and Mastercard, slightly less Prologis and Welltower. Energy, telecom equipment (Cisco), basic materials (Linde) and consumer staples (Coca‑Cola) all drifted down incrementally, underscoring that the real capital redeployment this quarter ran from AI-rich tech, energy and banks into health care and select consumer and industrial champions.

Read together, these moves say Legal & General is not abandoning AI; it is re-underwriting it with a more durable earnings base. The portfolio now leans on an AI infrastructure core, flanked by an expanding health-care complex that can work in both inflationary and slowing-growth regimes.

The big bet is that drugs and GLP‑1s become a second structural growth pillar comparable to AI, with AstraZeneca and Eli Lilly front and center. If AI sentiment wobbles or multiples compress, these names can still drive absolute returns via trial data, regulatory milestones and demand that is largely decoupled from the business cycle.

On the cyclicality spectrum, the fund is edging away from commodity and rate-sensitive exposures (energy, big banks) toward fee-based tollbooths in payments and software, plus oligopolistic consumer names. That should dampen drawdowns without sacrificing upside if innovation-led earnings continue to surprise.

Going into future quarters, watch three tells: whether they keep trimming the biggest AI winners, whether the health-care sleeve grows beyond ~10%, and whether banks continue to fund adds in capital-light franchises. If the current pattern holds, expect a portfolio increasingly defined by a handful of global platforms in chips, drugs, payments and streaming — with everything else sized to support, not to lead.